drugset / Trial / NCT01774045
A Dose Escalation Phase I Study of PDC-1421 Capsule Targeting in Depression
RandomizedParallel-groupTriple-blindOther
Summary
The purpose of this study is to evaluate the safety of PDC-1421 Capsule in healthy subject, find the effective adequate dose for the next stage of the study, and accumulate information of possible mechanism of its anti-depressive effect.
Timeline
- Start
- 2012-11
- Primary completion
- 2013-07
- Completion
- 2013-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PDC-1421 | Unknown | 380 mg | Oral |
| Subject | PDC-1421 | Unknown | 1140 mg | Oral |
| Subject | PDC-1421 | Unknown | 2280 mg | Oral |
| Subject | PDC-1421 | Unknown | 3800 mg | Oral |